↓ Skip to main content

Skin toxicities associated with tumor treating fields: case based review

Overview of attention for article published in Journal of Neuro-Oncology, August 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
17 Mendeley
Title
Skin toxicities associated with tumor treating fields: case based review
Published in
Journal of Neuro-Oncology, August 2017
DOI 10.1007/s11060-017-2612-8
Pubmed ID
Authors

Rimas V. Lukas, Kelley L. Ratermann, Eric T. Wong, John L. Villano

Abstract

The novel anti-mitotic based tumor treating fields (TTFields) is FDA approved for recurrent glioblastoma. Recently the phase III upfront trial combining the Novo TTF-100A device, called Optune, with temozolomide following concurrent radiation therapy and chemotherapy, demonstrated improvement in survival. Wider use of this novel therapy is expected. The most common adverse event is dermatologic, which dominates compared to the next most frequently observed adverse event of headaches, the incidence of which was even in both arms in the phase III registration trial for recurrent glioblastoma. Our case review outlines the presentation, treatment, and outcome of representative patients using TTFields. In summary, preventative strategies to inform and educate patients and operators can prevent many of these dermatological events. Skin toxicity in the setting of concurrent use of TTFields with other therapies such as bevacizumab is an unknown and will need to be closely followed.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Other 4 24%
Student > Ph. D. Student 4 24%
Student > Doctoral Student 3 18%
Researcher 2 12%
Professor > Associate Professor 2 12%
Other 2 12%
Readers by discipline Count As %
Medicine and Dentistry 5 29%
Unspecified 4 24%
Biochemistry, Genetics and Molecular Biology 3 18%
Agricultural and Biological Sciences 3 18%
Neuroscience 1 6%
Other 1 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 July 2018.
All research outputs
#10,524,164
of 13,210,683 outputs
Outputs from Journal of Neuro-Oncology
#1,274
of 1,972 outputs
Outputs of similar age
#195,413
of 265,491 outputs
Outputs of similar age from Journal of Neuro-Oncology
#29
of 61 outputs
Altmetric has tracked 13,210,683 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,972 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,491 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.